News | September 06, 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
The clinical research organisation located in Hyderabad is a USFDA inspected facility
The company to receive upfront and milestone payments, in addition to royalties
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
Subscribe To Our Newsletter & Stay Updated
